BibTex format
@article{Heathcote:2010,
author = {Heathcote, DA and Patel, H and Kroll, SH and Hazel, P and Periyasamy, M and Alikian, M and Kannegnti, SK and Jogalekar, AS and Scheiper, B and Barbazanges, M and Blum, A and Brackow, J and Siwicka, A and Pace, RD and Fuchter, MJ and Snyder, JP and Liotta, DC and Freemont, PS and Aboagye, EO and Coombes, RC and Barrett, AG and Ali, S},
journal = {J Med Chem},
pages = {8508--8522},
title = {A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration},
volume = {53},
year = {2010}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Cyclin-dependent protein kinases (CDKs) are central to the appropriate regulation of cell proliferation, apoptosis, and gene expression. Abnormalities in CDK activity and regulation are common features of cancer, making CDK family members attractive targets for the development of anticancer drugs. Here, we report the identification of a pyrazolo[1,5-a]pyrimidine derived compound, 4k (BS-194), as a selective and potent CDK inhibitor, which inhibits CDK2, CDK1, CDK5, CDK7, and CDK9 (IC= 3, 30, 30, 250, and 90 nmol/L, respectively). Cell-based studies showed inhibition of the phosphorylation of CDK substrates, Rb and the RNA polymerase II C-terminal domain, down-regulation of cyclins A, E, and D1, and cell cycle block in the S and G/M phases. Consistent with these findings, 4k demonstrated potent antiproliferative activity in 60 cancer cell lines tested (mean GI= 280 nmol/L). Pharmacokinetic studies showed that 4k is orally bioavailable, with an elimination half-life of 178 min following oral dosing in mice. When administered at a concentration of 25 mg/kg orally, 4k inhibited human tumor xenografts and suppressed CDK substrate phosphorylation. These findings identify 4k as a novel, potent CDK selective inhibitor with potential for oral delivery in cancer patients.
AU - Heathcote,DA
AU - Patel,H
AU - Kroll,SH
AU - Hazel,P
AU - Periyasamy,M
AU - Alikian,M
AU - Kannegnti,SK
AU - Jogalekar,AS
AU - Scheiper,B
AU - Barbazanges,M
AU - Blum,A
AU - Brackow,J
AU - Siwicka,A
AU - Pace,RD
AU - Fuchter,MJ
AU - Snyder,JP
AU - Liotta,DC
AU - Freemont,PS
AU - Aboagye,EO
AU - Coombes,RC
AU - Barrett,AG
AU - Ali,S
EP - 8522
PY - 2010///
SP - 8508
TI - A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration
T2 - J Med Chem
VL - 53
ER -
